Carrier screening
The American College of Obstetricians and Gynecologists recommends universal hemoglobinopathy testing for those planning pregnancy.[40]American College of Obstetricians and Gynecologists. Practice advisory: hemoglobinopathies in pregnancy. Aug 2022 [internet publication].
https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/08/hemoglobinopathies-in-pregnancy
[41]American College of Obstetricians and Gynecologists. Committee opinion no. 690: carrier screening in the age of genomic medicine. Mar 2017 [internet publication].
https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-in-the-age-of-genomic-medicine
Hemoglobin electrophoresis or molecular genetic testing should be performed when planning pregnancy, or at the initial prenatal visit if there are no previous test results available.[40]American College of Obstetricians and Gynecologists. Practice advisory: hemoglobinopathies in pregnancy. Aug 2022 [internet publication].
https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/08/hemoglobinopathies-in-pregnancy
If a woman is found to be a carrier, her reproductive partner should be offered screening.[41]American College of Obstetricians and Gynecologists. Committee opinion no. 690: carrier screening in the age of genomic medicine. Mar 2017 [internet publication].
https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-in-the-age-of-genomic-medicine
Information and counseling should be offered alongside screening.[41]American College of Obstetricians and Gynecologists. Committee opinion no. 690: carrier screening in the age of genomic medicine. Mar 2017 [internet publication].
https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-in-the-age-of-genomic-medicine
[42]American College of Obstetricians and Gynecologists. Committee opinion no. 691: carrier screening for genetic conditions. Mar 2017 [internet publication].
https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions
Thorough genetic counseling, including a discussion of reproductive options and the option of intrauterine transfusion, should be offered to all individuals who test positive during screening.[37]MacKenzie TC, Amid A, Angastiniotis M, et al. Consensus statement for the perinatal management of patients with alpha thalassemia major. Blood Adv. 2021 Dec 28;5(24):5636-9.
https://ashpublications.org/bloodadvances/article/5/24/5636/477884/Consensus-statement-for-the-perinatal-management
http://www.ncbi.nlm.nih.gov/pubmed/34749399?tool=bestpractice.com
[39]National Health Service (UK). Screening for sickle cell and thalassaemia. Oct 2022 [internet publication].
https://www.nhs.uk/pregnancy/your-pregnancy-care/screening-for-sickle-cell-and-thalassaemia
Prenatal diagnosis
Preimplantation genetic testing to prevent a pregnancy with alpha-thalassemia major is an option for prospective parents considering in vitro fertilization.[37]MacKenzie TC, Amid A, Angastiniotis M, et al. Consensus statement for the perinatal management of patients with alpha thalassemia major. Blood Adv. 2021 Dec 28;5(24):5636-9.
https://ashpublications.org/bloodadvances/article/5/24/5636/477884/Consensus-statement-for-the-perinatal-management
http://www.ncbi.nlm.nih.gov/pubmed/34749399?tool=bestpractice.com
Available tests for patients who are already pregnant include chorionic villus sampling (typically performed at 10-12 weeks' gestation in the US; 11-14 weeks' gestation in the UK) and amniocentesis (typically performed after 15 weeks' gestation).[36]ACOG Committee on Obstetrics. ACOG practice bulletin no. 78: hemoglobinopathies in pregnancy. Obstet Gynecol. 2007 Jan;109(1):229-37.
http://www.ncbi.nlm.nih.gov/pubmed/17197616?tool=bestpractice.com
[37]MacKenzie TC, Amid A, Angastiniotis M, et al. Consensus statement for the perinatal management of patients with alpha thalassemia major. Blood Adv. 2021 Dec 28;5(24):5636-9.
https://ashpublications.org/bloodadvances/article/5/24/5636/477884/Consensus-statement-for-the-perinatal-management
http://www.ncbi.nlm.nih.gov/pubmed/34749399?tool=bestpractice.com
[39]National Health Service (UK). Screening for sickle cell and thalassaemia. Oct 2022 [internet publication].
https://www.nhs.uk/pregnancy/your-pregnancy-care/screening-for-sickle-cell-and-thalassaemia
These are invasive tests and carry a risk of fetal loss.
Ultrasound is an important noninvasive means of detecting alpha-thalassemia major in at-risk pregnancies and may reduce the need for invasive testing.[59]Li X, Zhou Q, Zhang M, et al. Sonographic markers of fetal alpha-thalassemia major. J Ultrasound Med. 2015 Feb;34(2):197-206.
http://www.ncbi.nlm.nih.gov/pubmed/25614392?tool=bestpractice.com
[60]Norton ME, Chauhan SP, Dashe JS; Society for Maternal-Fetal Medicine. Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis. Am J Obstet Gynecol. 2015 Feb;212(2):127-39.
https://www.ajog.org/article/S0002-9378(14)02443-0/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/25557883?tool=bestpractice.com
[61]Harn-A-Morn P, Wanapirak C, Sirichotiyakul S, et al. Effectiveness of ultrasound algorithm in prenatal diagnosis of hemoglobin Bart's disease among pregnancies at risk. Int J Gynaecol Obstet. 2022 Nov;159(2):451-6.
http://www.ncbi.nlm.nih.gov/pubmed/35152406?tool=bestpractice.com
It is usually performed relatively late in pregnancy.
Testing of fetal DNA in maternal circulation is emerging as a noninvasive prenatal test for hemoglobinopathies such as thalassemia and sickle cell disease.[40]American College of Obstetricians and Gynecologists. Practice advisory: hemoglobinopathies in pregnancy. Aug 2022 [internet publication].
https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/08/hemoglobinopathies-in-pregnancy
[62]Hudecova I, Chiu RW. Non-invasive prenatal diagnosis of thalassemias using maternal plasma cell free DNA. Best Pract Res Clin Obstet Gynaecol. 2017 Feb;39:63-73.
http://www.ncbi.nlm.nih.gov/pubmed/27887921?tool=bestpractice.com
[63]Yang X, Ye Y, Fan D, et al. Non‑invasive prenatal diagnosis of thalassemia through multiplex PCR, target capture and next‑generation sequencing. Mol Med Rep. 2020 Aug;22(2):1547-57.
https://www.spandidos-publications.com/10.3892/mmr.2020.11234
http://www.ncbi.nlm.nih.gov/pubmed/32627040?tool=bestpractice.com
Newborn screening
Alpha-thalassemia is not included in the United States Recommended Uniform Screening Panel for state newborn screening programs. However, current screening methodologies used to detect sickle cell disease (reported by all states) also detect alpha-thalassemia.[35]Bender MA, Yusuf C, Davis T, et al. Newborn screening practices and alpha-thalassemia detection - United States, 2016. MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1269-72.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6936a7.htm
http://www.ncbi.nlm.nih.gov/pubmed/32915167?tool=bestpractice.com
Asymptomatic patient with microcytosis
Screening can also be performed in an asymptomatic patient with mild anemia and microcytosis to establish a diagnosis and thus avoid unnecessary and perhaps even harmful iron supplementation.